Myeloperoxidase

drug
On this page

Also known as LactoperoxidaseMPOMYELOPEROXIDASE COMPONENT OF E-101MYELOPEROXIDASE COMPONENT OF MPOE-101

Summary

Myeloperoxidase (CHEMBL2107858) is a phase-3 clinical-stage enzyme; indicated across 1 condition.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Enzyme
  • Indications: 1 condition
  • Clinical trials: 1

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2107858
NameMyeloperoxidase
TypeEnzyme
Max phase3

Also known as: Lactoperoxidase, MPO, Myeloperoxidase, MYELOPEROXIDASE COMPONENT OF E-101, MYELOPEROXIDASE COMPONENT OF MPO; E-101, MYELOPEROXIDASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

PhaseTrials
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05342272PHASE3COMPLETEDComparison of Gum® HydralTM Moisturizing Gel and Biotene® Oral Gel in Dry Mouth Sensation Reduction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.